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Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, genetically-mediated systemic disease most
often caused by chronic, uncontrolled complement activation that leads to systemic thrombotic microangiopathy
(TMA) and renal and other end-organ damage.
Methods: The global aHUS Registry, initiated in April 2012, is an observational, noninterventional, multicenter
registry designed to collect demographic characteristics, medical and disease history, treatment effectiveness
and safety outcomes data for aHUS patients. The global aHUS Registry will operate for a minimum of 5 years of
follow-up. Enrollment is open to all patients with a clinical diagnosis of aHUS, with no requirement for identified
complement gene mutations, polymorphisms or autoantibodies or particular type of therapy/management.
Results: As of September 30, 2014, 516 patients from 16 countries were enrolled. At enrollment, 315 (61.0 %)
were adults (≥18 years) and 201 (39.0 %) were <18 years of age. Mean (standard deviation [SD]) age at diagnosis
was 22.7 (20.5) years. Nineteen percent of patients had a family history of aHUS, 60.3 % had received plasma
exchange/plasma infusion, 59.5 % had a history of dialysis, and 19.6 % had received ≥1 kidney transplant. Overall,
305 patients (59.1 %) have received eculizumab.
Conclusions: As enrollment and follow-up proceed, the global aHUS Registry is expected to yield valuable baseline,
natural history, medical outcomes, treatment effectiveness and safety data from a diverse population of
patients with aHUS.
Trial registration: US National Institutes of Health www.ClinicalTrials.gov Identifier NCT01522183. Registered
January 18, 2012.
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Atypical hemolytic uremic syndrome (aHUS) is a rare,
genetic, life-threatening systemic disease that has an
incidence of one to two cases per million [1, 2]. It is
most often caused by chronic, uncontrolled activation of
the complement system, which leads to activation of
endothelial cells, recruitment of platelets and thrombotic
microangiopathy (TMA) [1, 3]. Patients of all ages with
aHUS have a lifelong, unpredictable risk for clinical
manifestations, each potentially leading to end-stage* Correspondence: christoph.licht@sickkids.ca
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damage, and/or death [1, 2, 4]. Recent findings from an
observational study in France of 214 patients with aHUS
showed that 29 % and 56 % of children and adults, re-
spectively, progressed to ESRD or death within a year of
follow-up [2]. Findings from another case series of 273
patients demonstrated that 79 % of aHUS patients have
permanent renal damage, require dialysis or die within
3 years of diagnosis [4].
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ment regulators or proteins, including C3, CFB, CFH, CFI,
MCP (CD46) and CFH-CFHR genomic rearrangements,
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However, evidence of complement gene mutations, poly-
morphisms and/or autoantibodies is not required for the
diagnosis of aHUS [6, 7]. Additionally, components of the
coagulation and other pathways can modulate comple-
ment activation—potentially pathogenic mutations or
polymorphisms in genes encoding thrombomodulin
(THBD, CD141), diacylglycerol kinase ε (DGKE) and
plasminogen (PLG) [8–10] have been identified in small
numbers of patients.
Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.,
Cheshire, CT, USA) is a terminal complement inhibitor
that is approved for the treatment of aHUS [11, 12].
Eculizumab initially was shown to be effective and well
tolerated in two pivotal prospective studies in primarily
adult populations of aHUS with evidence of progressing
TMA and with long disease duration and chronic kidney
disease [13, 14], as well as in a retrospective analysis of
pediatric patients with aHUS [15]; these studies led to
marketing authorization of eculizumab. Later, a larger
prospective study in an exclusively adult population
[16] and the first prospective study in a pediatric
population [17] also supported the efficacy and safety
of eculizumab.
Patient registries have been identified as tools to
characterize the natural history of a disease, to evaluate
clinical therapies, to monitor drug safety and to meas-
ure quality of care [18, 19]. A single, global registry
with multiple participating centers worldwide can
optimize patient enrollment, which is particularly
important for ultra-rare disease states like aHUS. Data
generated from an aHUS registry with maximal patient
and physician participation can advance epidemio-
logical characterization and inform scientific inquiry
and discourse on important issues, such as natural
history, systemic manifestations, genotype/phenotype
correlations, optimal patient management and long-term
treatment outcomes. Also, a global registry provides
opportunity for successful partnership between worldwide
academia and industry, driven by the shared goal of
improving outcomes for patients with aHUS.
Initiated in April 2012, the observational, noninter-
ventional, multicenter, global aHUS Registry has been
designed to prospectively collect demographic, disease
characteristic and treatment information for all eli-
gible patients with aHUS, regardless of treatment
received. The industry-sponsored Registry also fulfills
postmarketing regulatory requirements to provide
long-term follow-up on patients treated with eculizu-
mab. This current report describes the methodology
for the development of the global aHUS Registry, and
presents baseline demographic and disease character-
istics, as well as data on treatment of aHUS in the
clinical practice setting.Methods
The global aHUS Registry (US National Institutes of
Health www.ClinicalTrials.gov Identifier NCT01522183)
was initiated in April 2012 with the support of Alexion
Pharmaceuticals, Inc. The objectives of the aHUS
Registry are as follows: 1) to assess the long-term
effects of aHUS, including clinical outcomes such as
TMA complications, and morbidity and mortality in
aHUS patients receiving eculizumab treatment or other
disease management; and 2) to collect and evaluate
safety and effectiveness data specific to the use of eculi-
zumab in aHUS patients.
Scientific oversight, governance and coordination are
provided by an independent scientific advisory board
(SAB), whose members offer expertise in key specialties
related to management of aHUS (e.g., adult and pediatric
nephrologists, hematologists, and/or transplant nephrolo-
gists/surgeons) and also include representation from
Alexion Pharmaceuticals, Inc. The term of SAB member-
ship is 2 years. A member may serve more than one term
and also may terminate their membership at any time by
notifying the SAB Chairperson.
The SAB coordinates development of scientific publi-
cations, including advising on analyses and scientific
questions of interest, providing feedback on publication
goals and logistics, contributing to the publication plan,
establishing criteria for review/approval of external
requests for analyses and publications, reviewing publi-
cation drafts and counseling individuals who publish
data collected from the aHUS Registry. Registry partici-
pants and nonparticipating physicians may request data
access or specific analyses by submitting a concept sheet
or contacting the SAB through the Registry website
(when available) for evaluation.
The protocol was approved by the institutional review
board at each participating center or by an independent
ethics committee, where required, and was conducted in
accordance with International Conference on Harmonisa-
tion Good Clinical Practice Guidelines and the Declaration
of Helsinki. All patients provided written informed consent
before study participation.
The forthcoming global aHUS Registry website will
be programmed and maintained by a vendor specializ-
ing in the development of web-based electronic data
collection systems. Investigators will have access to
the secure website of the aHUS Registry for entering
and accessing patient data online, which will then be
stored at a secure and confidential location. Physicians
will be able to access the aHUS Registry website at any
time for the following purposes: entering and editing
data, accessing important documents (frequently asked
questions, reminders, etc.), responding to online queries,
accessing posted news items, sending/responding to mes-
sages, posing questions and accessing standard reports,
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data reports.
Written informed consent is provided by patients or
their parents/guardians, as deemed applicable by institu-
tional review boards and/or independent ethics commit-
tees. Clinicians were encouraged to enroll patients of all
ages who have already received a clinical diagnosis of
aHUS. Diagnosis of aHUS is not performed as part of
the Registry protocol. Patients are not required to have
an identified complement gene mutation or factor H
autoantibody, nor are they required to have previous
or ongoing treatment with eculizumab. Individuals
with evidence of Shiga toxin-producing Escherichia
coli infection or with ADAMTS13 activity ≤5 % (the
level consistent with a diagnosis of thrombotic throm-
bocytopenic purpura) are excluded.
All necessary disease history information will be gath-
ered from the patient’s medical records. During enroll-
ment and every 6 months thereafter, the following data
are collected as available: patient demographics, med-
ical and disease history, symptomatology, appropriate
laboratory results (including those from genetic tests),
TMA complications, associated treatments and con-
comitant medications, clinical and patient-reported
outcomes, safety of eculizumab and information re-
garding treatment or disease management. During each
assessment period, physicians will note changes in a pa-
tient’s clinical status since the last assessment period.
Symptoms and signs listed on the case report forms are
renal (edema, hypertension, proteinuria), gastrointes-
tinal (liver necrosis, hepatitis, pancreatitis, diabetes
mellitus), cardiovascular (cardiac insufficiency/failure,
vasculopathy/atherosclerosis, tachycardia), central ner-
vous system (confusion, focal neurological deficit,
ocular defects, headache) and pulmonary (hemorrhage,
edema, shortness of breath). Clinicians have the option
to list additional symptoms for these organ systems.
Occurrences of multisystemic symptoms (i.e., symp-
toms/signs categorized under more than one organ
system) also are recorded. Baseline values were defined
as those collected at time of Registry enrollment or
before the first dose of eculizumab (for patients who
received eculizumab). Safety evaluations included
adverse events and/or side effects associated with eculizu-
mab treatment and other management strategies and
measurement of human anti-human antibodies. Adverse
events of interest included meningococcal and other
serious infections, malignancy, renal impairment, hepatic
impairment, sepsis and infusion reactions.
The data cutoff for this analysis was September 30,
2014. Patients with all of the following data were
included in the current analysis of enrollment charac-
teristics: 1) date of birth, gender, Registry enrollment
date; 2) knowledge of treatment with eculizumab orno previous eculizumab treatment; and 3) for eculizumab-
treated patients, date of first eculizumab dose. Patients
were stratified by age at enrollment into the Registry.
Descriptive statistical analysis was performed to
summarize demographics and clinical data. Proportions
were calculated for categorical measures and summary
statistics (n, mean, standard deviation and median) for
continuous measures. All data analyses were performed
in a validated statistical programming environment using
SAS® statistical software version 9.2.
Results
As of September 30, 2014, 195 clinical sites in 17
countries were open to enrollment and a total of 516
patients were enrolled. Table 1 summarizes baseline
demographic characteristics among pediatric (n = 201;
39.0 %) and adult (n = 315; 61.0 %) patients, most of
whom were Caucasian and from the United States or
Western Europe.
Clinical characteristics of patients in the global aHUS
Registry are shown in Table 2. Pediatric and adult
patients were a mean of 4.3 and 34.5 years of age,
respectively, at aHUS diagnosis. Forty-six adult patients
(14.6 %) had aHUS symptom onset at <18 years of age,
and 41 (13.0 %) were diagnosed with aHUS at <18 years
of age. Overall, 99 patients (19.2 %) reported a family
history of aHUS. Although 307 patients (59.5 %) re-
ported a history of dialysis, only 101 (19.6 %) underwent
1 or more renal transplantations, which occurred more
frequently in adult compared with pediatric patients.
Most patients had a history of plasma exchange/plasma
infusion (PE/PI) and/or dialysis use, although these
management strategies were used more commonly for
adult patients compared with pediatric patients. Prior to
Registry enrollment, 274 patients (53.1 %) were treated
with eculizumab. Overall, 305 total patients (59.1 %)
enrolled in the Registry, including 117 pediatric patients
(58.2 %) and 188 adult patients (59.7 %), have been
treated with eculizumab.
Discussion
This report describes the initial enrollment, pattern of
global participation and types of data gathered in the
industry-sponsored global aHUS Registry, and outlines
baseline demographic and clinical characteristics of
current participants. While aHUS and TMA registries
have been established previously [4, 20, 21], the global
aHUS Registry is the largest and the only one to include
aHUS patients both treated and not treated with eculizu-
mab. Overall, patients were diagnosed with aHUS soon
after presenting with initial symptoms. While historically,
aHUS was thought to manifest primarily in children [1],
53 % of current Registry participants were adults at
diagnosis. This is similar to findings from a recent aHUS
Table 1 Patient Demographics in the Global aHUS Registry
Characteristic Pediatric patientsa (n = 201) Adult patientsa (n = 315) Total (N = 516)
Age at enrollment, years
Mean (SD) 8.2 (4.9) 39.7 (15.4) 27.4 (19.7)
Median (range) 8.3 (0.0–17.9) 38.3 (18.0–81.8) 24.3 (0.0–81.8)
Age category at time of enrollment, n (%)
<2 22 (10.9) — 22 (4.3)
2 to <5 41 (20.4) — 41 (7.9)
5 to <12 82 (40.8) — 82 (15.9)
12 to <18 56 (27.9) — 56 (10.9)
18 to <30 — 102 (32.4) 102 (19.8)
30 to <40 — 73 (23.2) 73 (14.1)
40 to <50 — 61 (19.4) 61 (11.8)
≥50 — 79 (25.1) 79 (15.3)
Female, n (%) 81 (40.3) 194 (61.6) 275 (53.3)
Race, n (%)
Caucasian 162 (80.6) 285 (90.5) 447 (86.6)
Other 27 (13.4) 10 (3.2) 37 (7.2)
Black 5 (2.5) 17 (5.4) 22 (4.3)
Asian 7 (3.5) 3 (1.0) 10 (1.9)
Country at time of enrollment, n (%)
United States 31 (15.4) 77 (24.4) 108 (20.9)
Germany 32 (15.9) 50 (15.9) 82 (15.9)
United Kingdom 33 (16.4) 33 (10.5) 66 (12.8)
Italy 20 (10.0) 45 (14.3) 65 (12.6)
Spain 24 (11.9) 13 (4.1) 37 (7.2)
France 3 (1.5) 25 (7.9) 28 (5.4)
Russia 17 (8.5) 10 (3.2) 27 (5.2)
Belgium 5 (2.5) 22 (7.0) 27 (5.2)
Australia 2 (1.0) 24 (7.6) 26 (5.0)
Israel 18 (9.0) 2 (0.6) 20 (3.9)
Austria 1 (0.5) 9 (2.9) 10 (1.9)
Canada 6 (3.0) 1 (0.3) 7 (1.4)
United Arab Emirates 6 (3.0) 0 (0.0) 6 (1.2)
Sweden 3 (1.5) 1 (0.3) 4 (0.8)
Switzerland 0 (0.0) 2 (0.6) 2 (0.4)
Finland 0 (0.0) 1 (0.3) 1 (0.2)
Year of enrollment
2012 1 (0.5) 20 (6.3) 21 (4.1)
2013 140 (69.7) 189 (60.0) 329 (63.8)
2014b 60 (29.9) 106 (33.7) 166 (32.2)
Deceased, n (%)c 1 (0.5) 14 (4.4) 15 (2.9)
aHUS atypical hemolytic uremic syndrome, SD standard deviation
aCategorized by age at enrollment in the Registry
bThrough September 30, 2014
cEach of these causes of death were reported in 1 patient: acute myeloid leukemia; Aspergillus infection; cardiomyopathy; continuous gastrointestinal bleeding;
gastrointestinal perforation; liver metastases; malignant cardiac arrhythmias; protracted cardiogenic shock and ventricular tachycardia; renal failure in addition
to aHUS and pancreatic cancer; respiratory arrest probably due to cytomegalovirus infection; respiratory failure due to pneumonia; respiratory failure secondary to
bleomycin lung injury; serious infection leading to multiple organ failure; unknown; withdrawal from dialysis and prostate cancer
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Table 2 Clinical Characteristics of Patients in the Global aHUS Registry
Characteristic Pediatric patients (n = 201)a Adult patients (n = 315)a Total (N = 516)a
Age at initial symptoms, years
n 198 310 508
Mean (SD) 4.1 (3.9) 33.6 (18.3) 22.1 (20.4)
Median (range) 2.9 (0.0–16.3) 31.1 (0.1–81.8) 19.2 (0.0–81.8)
Age categories, n (%)
<2 87 (43.9) 12 (3.9) 99 (19.5)
2 to <5 40 (20.2) 9 (2.9) 49 (9.6)
5 to <12 60 (30.3) 14 (4.5) 74 (14.6)
12 to <18 11 (5.6) 11 (3.5) 22 (4.3)
18 to <30 — 95 (30.6) 95 (18.7)
30 to <40 — 71 (22.9) 71 (14.0)
40 to <50 — 34 (11.0) 34 (6.7)
≥50 — 64 (20.6) 64 (12.6)
Age at diagnosis, years
n 201 313 514
Mean (SD) 4.3 (4.0) 34.5 (17.9) 22.7 (20.5)
Median (range) 3.1 (0.0–16.3) 31.5 (0.1–81.8) 19.7 (0.0–81.8)
Age categories, n (%)
<2 86 (42.8) 10 (3.2) 96 (18.7)
2 to <5 39 (19.4) 6 (1.9) 45 (8.8)
5 to <12 63 (31.3) 11 (3.5) 74 (14.4)
12 to <18 13 (6.5) 14 (4.5) 27 (5.3)
18 to <30 — 98 (31.3) 98 (19.1)
30 to <40 — 71 (22.7) 71 (13.8)
40 to <50 — 35 (11.2) 35 (6.8)
≥50 — 68 (21.7) 68 (13.2)
Disease duration from diagnosis to enrollment, years
n 201 313 514
Mean (SD) 4.0 (4.1) 5.2 (7.8) 4.7 (6.6)
Median (range) 2.4 (0.0–17.1) 1.6 (0.0–50.6) 1.9 (0.0–50.6)
Family history of aHUS, n (%) 41 (20.4) 58 (18.4) 99 (19.2)
History of PE/PI, n (%) 107 (53.2) 204 (64.8) 311 (60.3)
History of dialysis, n (%) 107 (53.2) 200 (63.5) 307 (59.5)
History of kidney transplantation, n (%) 25 (12.4) 76 (24.1) 101 (19.6)
History of eculizumab use prior to enrollment, n (%) 106 (52.7) 168 (53.3) 274 (53.1)
aHUS atypical hemolytic uremic syndrome, PE/PI plasma exchange/plasma infusion, SD standard deviation
aFor each parameter, percentages were calculated based on the number of patients with non-missing observations in each group
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France occur in patients older than 18 years [2].
However, the age distribution of participants in the
Registry will be influenced by the focus of sites (i.e.,
adult or pediatric) that are currently open.
Historically, PE/PI has been used to manage aHUS
[22] by supplying functional natural regulators of
complement, thus temporarily maintaining hematologicparameters [1, 22, 23]. Eculizumab, the only approved
treatment for aHUS [11, 12], has been shown to inhibit
complement-mediated TMA and is well tolerated [13, 14].
Several current guidelines recommend the immediate
initiation of eculizumab for pediatric and adult patients
once a diagnosis of aHUS is made [6, 7, 24, 25]. Thus far,
59.1 % of patients in the Registry have been treated with
eculizumab. As the Registry grows, it will become more
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compared with patients who are managed with PE/PI
or other options, in a larger population than was
included in the prospective clinical trial program for
eculizumab [13, 14, 16, 17]. In the future, it will be of par-
ticular interest to evaluate longer-term outcomes to help
elucidate optimal treatment with eculizumab.
Limitations of the Registry include possible underre-
porting of outcomes, missing data, and/or inadequate
follow-up. Robustness of data gathered depends on the
quality of data entry, number of aHUS patients who
enroll, the diversity of their demographic and disease
characteristics, including age and disease duration, and
retention of recruited patients. Thus far, enrolled
patients have had a mean of 5-year histories of aHUS
before Registry enrollment. Future enrollment of
patients who are newly diagnosed with aHUS will allow
for analysis of more contemporary treatment and
management approaches. Other limitations include the
potential for varying interpretation of baseline disease
characteristics by enrolling physicians. Increased clin-
ician participation and collection of complete informa-
tion will optimize the quality of Registry results and
inform forthcoming analyses.
Future analyses from the global aHUS Registry will be
conducted to increase understanding of the natural
history and progression of the disease. Data gathered dur-
ing the minimum 5-year follow-up period are collected
from clinicians worldwide and will be valuable to help de-
scribe aHUS presentation, progression with or without
eculizumab therapy, and patient outcomes. Thus far, ob-
servational studies in aHUS patients have led to varying
conclusions regarding the effect of genetic background on
prognosis [2, 4]. Although complement gene mutations,
polymorphisms or factor H autoantibodies typically are
identified in up to 70 % of patients [2, 4, 26], they are not
required for a diagnosis of aHUS [6, 7]. As part of ongoing
research efforts, future analyses of the global aHUS Regis-
try may also help to determine the relative degree to
which genetic and other patient factors (e.g., age, gender
and ethnicity) predict the development and clinical
course of complement-mediated TMA complications.
Atypical hemolytic uremic syndrome is typically
characterized by renal involvement [1]; however, the
medical literature increasingly is reporting extrarenal
complications of the disease [4, 27], including cardio-
vascular, neurological, pulmonary, and gastrointestinal.
Future analyses will help to better characterize the
development and progression of extrarenal and multi-
systemic complications. Several conditions that may
potentially further increase complement activity are
known to uncover an underlying diagnosis of aHUS
and place patients at increased risk for renal and/or
extrarenal organ damage [1, 28, 29]. The Registry is opento all patients with a clinical history of aHUS, including
those with these types of comorbid conditions that have
been associated with TMA and/or aHUS, including auto-
immune disease, malignancy, malignant hypertension,
pregnancy-associated conditions of preeclampsia and
HELLP (hemolysis, elevated liver enzymes, low platelet
count) syndrome, and scleroderma [4, 7, 30, 31]. Inclusion
of these patients may allow for further characterization of
the relationship between these conditions and aHUS in fu-
ture analyses. Finally, because enrollment in the Registry
is not contingent upon receipt of eculizumab, data com-
paring the long-term outcomes of patients treated with
eculizumab and patients managed with supportive therap-
ies, including PE/PI, may be included in future analyses.
Conclusions
Finally, data derived from the aHUS Registry may also be
valuable in defining strategies for optimization of patient
care. With inclusion of both treated and untreated
patients, the Registry will make it possible to characterize
the long-term effectiveness and safety profile of eculi-
zumab across a diverse patient population.
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